| Catalog No. | Size | Price (USD) |
| 10604-R241-50 | 50 µL | $177.58 |
| 10604-R241-100 | 100 µL | $340.51 |
General Information
| Product name | Recombinant Anti-C5a Antibody, Rabbit Monoclonal |
| Validated applications | ELISA (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human Complement C5 |
| Immunogen | Recombinant Human Complement C5a Protein (Catalog#10604-HNAE) |
| Preparation | This antibody was obtained from a rabbit immunized with purified, recombinant Human Complement C5a (rh Complement C5a ; Catalog#10604-HNAE; NP_001726.2; Leu679-Arg751). |
| Source | Monoclonal Rabbit IgG Clone #241 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-C5a Antibody; Anti-C5b Antibody; Anti-C5D Antibody; Anti-CPAMD4 Antibody; Anti-ECLZB Antibody
Background Information
| Full Name | complement component 5 |
| Description | C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 α-chain during the classical, alternative, and lectin pathways of complement activation. The structure of C5a includes a core region consisting of four, anti-parallel alpha-helices held together by three disulfide linkages and a structured C-terminal tail, and C5a is rapidly metabolised by carboxypeptidase B to a 73 amino acid low activity form, C5a des-Arg. C5a is an extremely potent proinflammatory mediator, as well as a potent chemotactic factor for neutrophils and other leukocytes. It causes histamine release, increases in vascular permeability, induces several cytokines production from leukocytes, enhances neutrophil-endothelial cell adhesion, and augments the humoral and cell-mediated immune response. C5a is quickly metabolised by carboxypeptidases, forming the less potent C5adesArg. Acting via a classical G protein-coupled receptor, CD88, C5a and C5adesArg exert a number of effects essential to the innate immune response, while their actions at the more recently discovered non-G protein-coupled receptor, C5L2 (or GPR77), remain unclear. The widespread expression of C5a receptors throughout the body allows C5a to elicit a broad range of effects. Thus, C5a has been found to be a significant pathogenic driver in a number of immuno-inflammatory diseases, making C5a inhibition an attractive therapeutic strategy. C5a is a strong chemoattractant and is involved in the recruitment of inflammatory cells such as neutrophils, eosinophils, monocytes, and T lymphocytes, in activation of phagocytic cells and release of granule-based enzymes and generation of oxidants, all of which may contribute to innate immune functions or tissue damage. Accordingly, the anaphylatoxin C5a is implicated in a variety of diseases such as rheumatoid arthritis, systemic lupus erythematosus, reperfusion injury, Alzheimer's disease, and sepsis. |
| Related Pathways |
|
| References |
|
